Empagliflozin Effect on Glucose Toxicity in Type 2 Diabetes Patients - a Randomized, Open-label, Controlled, Parallel Group, Exploratory Study
Latest Information Update: 20 May 2024
At a glance
- Drugs Empagliflozin (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms OXIDISE
- Sponsors GWT-TUD GmbH
- 13 May 2024 Planned End Date changed from 1 Aug 2023 to 3 May 2023.
- 13 May 2024 Planned primary completion date changed from 1 Feb 2023 to 3 May 2023.
- 13 May 2024 Status changed from active, no longer recruiting to withdrawn prior to enrolment. (poor recruitment)